# US 2019/0375805 A1 · Naf-1 derived peptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375805 A1
- Document ID: US20190375805A1
- Status: Published application
- Kind: A1
- Application number: 16/485,980
- Filed: 2018-02-12
- Published: 2019-12-12
- Earliest claimed: 2017-02-14
- Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem
- Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
- Inventors: Rachel NECHUSHTAI; Assaf FRIEDLER; Anat IOSUB-AMIR; Merav DARASH-YA-HANA; Yang-Sung SOHN; Dorit MICHAELI
- Web page: https://patentgrep.com/patent/US20190375805A1

## CPC

- C07K 14/47: from mammals
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides peptides comprising a sequence derived from the human NAF-1 protein, analogs of said sequence or a retro-inverso sequence of said peptide or analog. The conjugates of such peptides are provided as well. The peptides and the conjugates of the present invention are useful in treating cancer, and in particular cancer in which the expression of NAF-1 is enhanced.

## Claims

### Claim at position 1

1-37. (canceled)

### Claim 38

A peptide comprising:
(a) the amino acid sequence FLGVLALLGYLAVRPFLPKKKQQK set forth as SEQ ID NO: 1;
(b) an analog of (a);
(c) a retro-inverso sequence of (a) or (b); or
(d) a fragment consisting of 17 to 23 consecutive amino acids of (a), (b) or (c);
wherein the peptide consists of 17 to 50 amino acids.

### Claim 39 (depends on 38)

The peptide of claim 38, wherein the analog comprises 1 to 6 amino acid modifications to SEQ ID NO: 1.

### Claim 40 (depends on 39)

The peptide of claim 39, wherein at least one modification is selected from the group consisting of: a conservative substitution of an amino acid residue; substitution of a lysine (Lys) residue for another positively charged amino acid; and substitution of at least one of the hydrophobic amino acids for an alanine (Ala) residue.

### Claim 41 (depends on 38)

The peptide of claim 38, wherein the analog comprises at least one D-amino acid residue or wherein the analog consists of D-amino acid residues.

### Claim 42 (depends on 40)

The peptide of claim 40, wherein at least one of the amino acid residues substituted with a D-amino acid residue is selected from an amino acid residue at position 10, 16 and 20 of SEQ ID NO: 1; or wherein the analog comprises the amino acid residues D-tyrosine, D-phenylalanine and D-lysine at positions 10, 16 and 20 of SEQ ID NO: 1, respectively.

### Claim 43 (depends on 42)

The peptide of claim 42, comprising an amino acid sequence selected from the group consisting of: FLGVLALLGyLAVRPfLPKkKQQK set forth as SEQ ID NO: 2; and flgvlallgylavrpflpkkkqqk set forth as SEQ ID NO: 3.

### Claim 44 (depends on 38)

The peptide of claim 38, comprising a retro-inverso sequence of SEQ ID NO: 1 or of an analog thereof.

### Claim 45 (depends on 44)

The peptide of claim 44, comprising the amino acid sequence kqqkkkplfprvalygllalvglf set forth as SEQ ID NO: 4.

### Claim 46 (depends on 38)

The peptide of claim 38, wherein the fragment consists of 17 to 23 consecutive amino acids of a sequence selected from SEQ ID NOs: 1, 2, 3 and 4.

### Claim 47 (depends on 38)

The peptide of claim 38, wherein said peptide consists of an amino acid sequence selected from SEQ ID NOs: 1, 2, 3 and 4, analog of SEQ ID NO: 1, and a fragment thereof.

### Claim 48 (depends on 38)

The peptide of claim 38, comprising an amino acid sequence having at least 70% identity to the SEQ ID NO: 1 or SEQ ID NO: 4.

### Claim 49 (depends on 38)

A conjugate of a peptide according to claim 38.

### Claim 50 (depends on 49)

The conjugate of claim 49, wherein the peptide is conjugated with a polyethylene glycol (PEG) molecule.

### Claim 51 (depends on 50)

The conjugate of claim 50, wherein the conjugate comprises a peptide consisting of SEQ ID NO: 2 and a PEG molecule comprising from 6 to 8 ethylene glycol monomers.

### Claim 52 (depends on 38)

A pharmaceutical composition comprising at least one peptide of claim 38 or a conjugate thereof.

### Claim 53 (depends on 52)

The pharmaceutical composition of claim 52, wherein the peptide consists of an analog of amino acid sequence selected from SEQ ID NOs: 1, 2, 3 and 4.

### Claim 54 (depends on 38)

A method for treating cancer in a subject in need thereof comprising administering a peptide of claim 38 or a conjugate thereof.

### Claim 55 (depends on 54)

The method of claim 54 wherein the cancer is associated with an enhanced expression of NAF-1 protein.

### Claim 56 (depends on 55)

The method of claim 55, wherein the cancer is selected from the group consisting of a breast, prostate, gastric, cervical, liver, pancreas, head, neck and laryngeal cancer.

### Claim 57 (depends on 53)

The method of claim 53, wherein the peptide or conjugate thereof are administered in combination with anti-cancer therapy.
